GL1X · GenesisL1 explorer

Research workbench

Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (nampt) inhibitors

Analyse Structure-based identification of ureas as novel nicotinamide… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4JR5
Type
protein
Length
941 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Nicotinamide phosphoribosyltransferase
EC
2.4.2.12
UniProt
P43490
Ligands
1LS, PO4
Pockets
7 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 41% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ANicotinamide phosphoribosyltransferase (EC 2.4.2.12)protein47142% helix, 19% strandP43490
BNicotinamide phosphoribosyltransferase (EC 2.4.2.12)protein47041% helix, 19% strandP43490

Ligands and binding sites

  • 1LS · 1-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(pyridin-3-ylmethyl)thiourea · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · 4 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18060.800.83891LS, PO4
27520.800.8477PO4, 1LS, EDO
37030.730.7965empty
4890.390.7714empty
5750.340.7615empty

Interfaces

1 interface between chains.

  • A–B · 4287 Ų buried · 77 hydrogen bonds · protein-protein

Compared structures

  • 4JR5 · Structure-based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.